Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 2:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 86 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: TriLipix Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction Between ABT-335, Rosuvastatin and Warfarin

NCT00487136
View directory record Official record
Conditions
Healthy
Interventions
Warfarin, warfarin plus ABT-335 plus rosuvastatin 5 mg, warfarin plus ABT-335 plus rosuvastatin 20 mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2012 · Synced Oct 26, 2026, 2:33 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Securing Employment and Economic Keys to Stability for Persons With Disabilities

NCT04394949
View directory record Official record
Conditions
Employment
Interventions
Center for Independent Living SEEKS Team, Usual Care
Behavioral · Other
Lead sponsor
Communication Institute International, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Littleton, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Oct 26, 2026, 2:33 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease

NCT03515213
View directory record Official record
Conditions
Huntington Disease
Interventions
Fenofibrate, Placebo
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 26, 2026, 2:33 PM EDT
Completed Phase 2 Interventional Results available

Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia

NCT00504829
View directory record Official record
Conditions
Dyslipidemia
Interventions
LCP-AtorFen, atorvastatin, fenofibrate
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 26, 2026, 2:33 PM EDT
Terminated Not applicable Interventional Results available

Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia

NCT00794963
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Pravastatin, Fenofibrate, Metformin, Orlistat, irbesartan, As selected by community physician
Drug · Other
Lead sponsor
Northwell Health
Other
Eligibility
19 Years to 79 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 26, 2026, 2:33 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood

NCT00639158
View directory record Official record
Conditions
Dyslipidemias, Coronary Heart Disease, Combined (Atherogenic) Dyslipidemia, Mixed Dyslipidemia
Interventions
ABT-335, placebo, atorvastatin, ezetimibe
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
543 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
118
States / cities
Birmingham, Alabama • Columbiana, Alabama • Hueytown, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2011 · Synced Oct 26, 2026, 2:33 PM EDT
Active, not recruiting Phase 2 Interventional

A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes

NCT04929379
View directory record Official record
Conditions
Diabetic Nephropathies
Interventions
Fenofibrate, Placebo
Drug · Other
Lead sponsor
Alessandro Doria
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Boston, Massachusetts • Burlington, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 26, 2026, 2:33 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Insulin Resistance in Non-alcoholic Fatty Liver Disease

NCT00252499
View directory record Official record
Conditions
Fatty Liver, Insulin Resistance
Interventions
rosiglitazone, fenofibrate, placebo for rosiglitazone, placebo for fenofibrate
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Oct 26, 2026, 2:33 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents

NCT00359281
View directory record Official record
Conditions
Healthy
Interventions
atorvastatin, simvastatin, ezetimibe, fenofibrate, dextromethorphan, Extended Release Niacin
Drug
Lead sponsor
Aegerion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 26, 2026, 2:33 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL

NCT01047683
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
18
States / cities
Sacramento, California • Golden, Colorado • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 26, 2026, 2:33 PM EDT
Recruiting Not applicable Interventional

The Ambient Light Multiple Myeloma Study

NCT05737732
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Circadian Effective Lighting, Circadian Ineffective Lightning (CIL)
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 26, 2026, 2:33 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Fenofibrate and Pharmacogenetic Impact in Dyslipidemia

NCT00613613
View directory record Official record
Conditions
Dyslipidemia
Interventions
fenofibrate
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 26, 2026, 2:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia

NCT00304993
View directory record Official record
Conditions
Metabolic Syndrome X, Insulin Resistance
Interventions
fenofibrate, niacin, rosiglitazone
Drug
Lead sponsor
Foundation Research, Florida
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Mar 21, 2006 · Synced Oct 26, 2026, 2:33 PM EDT
Completed Phase 3 Interventional Results available

Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)

NCT00542178
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Hypoglycemic Agents, Standard glycemia control, Intensive BP treatment, Standard BP control, Fenofibrate, Simvastatin, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
3,472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 26, 2026, 2:33 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.

NCT00300430
View directory record Official record
Conditions
Dyslipidemia, Coronary Heart Disease, Mixed Dyslipidemia
Interventions
ABT-335 and rosuvastatin calcium, ABT-335 and atorvastatin calcium, ABT-335 and simvastatin
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
1,911 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 23, 2009 · Synced Oct 26, 2026, 2:33 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

LXRA Gene Polymorphisms and Response to Fenofibrate

NCT00644592
View directory record Official record
Conditions
Healthy
Interventions
Fenofibrate capsule daily for 4 weeks, Fenofibrate
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Oct 26, 2026, 2:33 PM EDT
Completed Phase 2 Interventional Results available

An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

NCT02890992
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
alirocumab SAR236553 (REGN727), statins, ezetimibe, cholestyramine, fenofibrate, omega-3 fatty acids, nicotinic acid
Drug
Lead sponsor
Sanofi
Industry
Eligibility
8 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
St Louis, Missouri • Charlotte, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 26, 2026, 2:33 PM EDT
Terminated Phase 2Phase 3 Interventional

Fenofibrate and Propranolol in Burn Patients

NCT02452255
View directory record Official record
Conditions
Burn
Interventions
Fenofibrate, Placebo, Propranolol
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Up to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 26, 2026, 2:33 PM EDT
Completed No phase listed Observational Results available

Cardiovascular, Pulmonary, and Integrative Functional Phenotypes in COVID-19 Survivors - Effect of Fenofibrate

NCT05080192
View directory record Official record
Conditions
Covid19
Interventions
Fenofibrate, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 26, 2026, 2:33 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Insulin Resistance in Non-alcoholic Fatty Liver Disease

NCT01289639
View directory record Official record
Conditions
Fatty Liver
Interventions
fenofibrate, pioglitazone, placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 26, 2026, 2:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Micronized Fenofibrate on Fasting and Postprandial Lipoproteins, Inflammatory Mediators and Thrombosis

NCT00422396
View directory record Official record
Conditions
Hypertriglyceridemia With the Metabolic Syndrome
Interventions
Fenofibrate (drug)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 26, 2026, 2:33 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Study of Trilipix Effects on Lipids and Arteries

NCT01025492
View directory record Official record
Conditions
Dyslipidemia
Interventions
Trilipix, placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
30 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Oct 26, 2026, 2:33 PM EDT
Completed Phase 3 Interventional Results available

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

NCT01047501
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
80
States / cities
Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 26, 2026, 2:33 PM EDT
Active, not recruiting Phase 3 Interventional

Fenofibrate for Prevention of DR Worsening

NCT04661358
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Fenofibrate, Placebo
Drug · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years to 80 Years
Enrollment
563 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
66
States / cities
Glendale, California • Huntington Beach, California • Loma Linda, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 26, 2026, 2:33 PM EDT